Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioid Approvals: Congress Wants US FDA Guidance On Abuse Potential

Oct 01 2018

• By Derrick Gingery

Capitol House

Related Content

Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns

Feb 14 2018

Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities

Feb 22 2018

Opioid Bills Could Enhance US FDA Approval, Withdrawal Authority

Sep 19 2018

Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products

Sep 19 2018

Opioid Packaging: Is Non-Inferiority Enough For A New Claim?

Dec 12 2017

Curtain Falls On Opana ER As Endo Agrees To US FDA Withdrawal Request

Jul 06 2017

Over-Legislating On Opioids? US FDA May Get New Authorities And Unwanted Tasks

Jun 06 2018

Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era

Feb 22 2017

Related Companies

Endo, Inc.

Additional Topics

United States Legislation FDA Regulation Review Pathway BioPharmaceutical

More from Legislation

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window